Meta's new shopping agent rattled online travel stocks almost equally, but Booking Holdings and Expedia chose opposite responses to the threat. One strategy leaves a company dangerously exposed if Meta decides to cut out…
Cerebras stock slipped below its IPO price on the same day insiders filed to sell and a report surfaced questioning whether its anchor customer moved its fastest model to rival hardware.
The Senate came within seven votes of banning congressional stock trading, but a clause with nothing to do with stocks may have killed the whole effort. Here is what actually happened and what it…
Ten of eleven S&P sectors dropped in September as oil and Treasury yields surged together, yet one corner of the market kept climbing and now sits at its highest concentration in years.
Micron just posted its eighth straight earnings beat and a stock gain that tops 270% for the year, yet the CEO openly admits he cannot see when the memory shortage ends. That combination of…
Microsoft just posted its strongest quarterly stock gain in 35 years, but the rally left it barely above where it started the year and still below its all-time high. Whether November's earnings confirm a…
One sentence from New York Fed President John Williams sent rate-hike odds tumbling, but two other Fed governors told a very different story about where policy is headed before year's end.
A 100% tariff on imported drugs just expanded to cover every drugmaker in the country, yet the biotech market's most closely watched fund treated it like a non-event. The reason says everything about who…
Consumer confidence just hit its worst level in over a decade, yet the stocks that depend on American shoppers are barely flinching. Understanding why that calm exists, and how long it can last, matters…
uniQure lost more than a third of its value in a single session after Huntington's data spooked investors, but Wall Street's price target still points to triple-digit upside. Whether that gap represents opportunity or…
AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant…
Wall Street analysts are nearly unanimous that DraftKings is a buy, yet the stock just hit its lowest price since 2023 while a private rival with no sportsbook license is reportedly worth four times…
Michael Burry just swapped unlimited-horizon short positions for expiring put contracts on Micron, accepting a hard deadline to be right before a stock up 550% in a year reports earnings in hours.
Cathie Wood just dumped one of this year's biggest AI winners to load up on a stock that has barely moved, and the reasoning behind that swap reveals a lot about where she thinks…
A 49% capex spike and a lost bidding war cratered Dutch Bros shares, but one analyst just reloaded his Buy rating while shifting his valuation two years forward. The question is whether slowing foot…
Anthropic filed confidentially for an IPO at a valuation that would place it above some of the most established names in tech, yet its financials raise hard questions about whether public markets will price…
Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-burning biotech with no revenue and a likely share offering complicates any case for chasing the move.
Silver just recorded one of its worst stretches in decades, and the forces behind the selloff are still building pressure. Understanding what broke the metals trade could be the difference between catching a bounce…
Gold just suffered its steepest single-session drop in months, and the culprit had nothing to do with the metal itself. Tracing the chain of events reveals whether long-term holders should worry or whether something…
ARK Investment Management made three separate bets on Meta in September, selling rival AI giants to fund each purchase, even as Meta's expenses outpaced its revenue and a new competitor threatened its biggest growth…
